Holen Sie sich die Stockscreener-App
206.60
2.23%
-4.72
Handel nachbörslich:
206.65
0.05
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$211.32
Offen:
$211
24-Stunden-Volumen:
6.34M
Relative Volume:
0.89
Marktkapitalisierung:
$365.43B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.62B
KGV:
101.62
EPS:
2.0331
Netto-Cashflow:
$17.82B
1W Leistung:
+3.97%
1M Leistung:
-3.90%
6M Leistung:
-5.25%
1J Leistung:
+6.86%
1-Tages-Spanne:
$205.57
$211.00
1-Wochen-Bereich:
$190.75
$214.87
52-Wochen-Spanne:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at DZ Bank - MarketBeat
Benjamin Edwards Inc. Has $77.83 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance - MarketBeat
AbbVie (NYSE:ABBV) Stock Price Down 2.2%Here's What Happened - MarketBeat
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried - WSJ
ABBV Reiterated by Guggenheim -- Price Target Maintained at $249 - GuruFocus
10 Health Care Stocks With Whale Alerts In Today's SessionAbbVie (NYSE:ABBV), AtaiBeckley (NASDAQ:ATAI - Benzinga
AbbVie (NYSE: ABBV) Posts Q1 Revenue of $15B, Raises Guidance - Value The Markets
AbbVie Stock Beats Q1 Estimates as Skyrizi Hits $4.5B in a Single Quarter - TIKR.com
AbbVie option and FDA feedback reshape Aldeyra (Nasdaq: ALDX) drug plans - Stock Titan
Oppenheimer & Co. Inc. Sells 8,094 Shares of AbbVie Inc. $ABBV - MarketBeat
Fifth Third Bancorp Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Danske Bank A S Has $267.24 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts? - Yahoo Finance
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026 - GlobeNewswire Inc.
FDA filing for investigational alopecia areata treatment lifts AbbVie stock 3.65% - Traders Union
AbbVie stock jumps 3.65% as Q1 2026 earnings call announcement boosts sentiment - Traders Union
Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT - Insider Monkey
AbbVie Inc (ABBV) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 86/100 - GuruFocus
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings (NYSE:ABBV) - Seeking Alpha
AbbVie and adMare BioInnovations Award RIME Therapeutics to Advance Biotech Innovation in Quebec - Quiver Quantitative
ABBV Maintained by Morgan Stanley -- Price Target Raised to $278 - GuruFocus
Federated Hermes MDT Market Neutral ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Q1 earnings loom: Buy or sell the stock ahead of results? - MSN
AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says - marketscreener.com
New York State Teachers Retirement System Sells 39,154 Shares of AbbVie Inc. $ABBV - MarketBeat
ABBV Reiterates by Cantor Fitzgerald -- Price Target Maintained at $240 - GuruFocus
Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy - Yahoo Finance
AbbVie Stock Forecast: Trending Buy Calls From Analysts - TipRanks
ABBV shares surge with Skyrizi and Rinvoq sales offsetting Humira decline: weekly forecast - Traders Union
AbbVie Inc Stock (ABBV) Moved Up by 3.49% on Apr 30: A Full Analysis - TradingKey
Jennison Associates LLC Has $271.21 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
US Bancorp DE Sells 41,982 Shares of AbbVie Inc. $ABBV - MarketBeat
Every new Allē referral sign-up sends $10 to Skin Cancer Foundation - Stock Titan
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month - AbbVie News Center
AbbVie Inc. (NYSE:ABBV) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord raises Abbvie stock price target on strong quarter - Investing.com
Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act - BioSpace
Sarofim Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
BofA upgrades Abbvie stock rating on immunology strength - Investing.com
Invesco Charter Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie upgraded to Buy at BofA on durable growth - TipRanks
Goldman Sachs raises Abbvie stock price target on growth confidence - Investing.com
AbbVie Stock (US00287Y1091): Reports Strong Q1 2026 Results with EPS Beat - AD HOC NEWS
Goldman Sachs Enhanced U.S. Equity ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc (ABBV) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):